Pacira Ends Production of Sterile Injectable
Pacira Pharmaceuticals, a specialty pharmaceutical company, has discontinued all future production of DepoCyt in the US and Canada and DepoCyte in the European Union due to persistent technical issues specific to the DepoCyt(e) manufacturing process, said the company in a filing with the US Securities and Exchange Commission.
DepoCyte, a sterile, injectable suspension of the antimetabolite, cytarabine, encapsulated into multivesicular lipid-based particles, accounted for approximately 2.5% of the company’s total revenues in 2016.
In the second quarter of 2017, the company expects to record a charge of approximately $5.0 million related to the discontinuation of its DepoCyt(e) manufacturing. Approximately $2.5 million relates to the write-off of certain assets, $2.0 million relates to the remaining lease costs less an estimate of potential sub-lease income for the facility where DepoCyt(e) is manufactured, and $0.5 million relates to employee severance and other exit costs. The company expects that $3.3 million of the total charge will be paid in cash.
This decision does not affect any product that has already been distributed to customers or administered to patients.
Source: Pacira Pharmaceuticals